Breaking Finance News

Vetr Inc. announced Pfizer Inc. (NYSE:PFE), raising its target price to $36.36 today

Yesterday Pfizer Inc. (NYSE:PFE) traded -1.04% lower at $33.07. The company’s 50-day moving average is $34.14 and its 200-day moving average is $34.26. The last stock close price is down -4.48% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 2,474,112 shares of the stock were exchanged, down from an average trading volume of 18,868,500

Pfizer Inc. (NYSE:PFE) had its target price raised to $36.36 by Vetr Inc. in a report released 10/13/2016. The new target price indicates a possible upside of 0.10% based on the company's last stock close price.

See Chart Below

Pfizer Inc. (NYSE:PFE)

Pfizer Inc. has a 52 week low of $28.25 and a 52 week high of $37.39 with a P/E ratio of 29.01 The company’s market cap is currently $0.

In addition to Vetr Inc. reporting its target price, a total of 20 firms have issued a report on the stock. The consensus target price is $38.58 with 4 firms rating the stock a strong buy, 10 firms rating the stock a buy, 7 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

General Information About Pfizer Inc. (NYSE:PFE)

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company's segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the Premarin family of products. Its biotechnology products include BeneFIX, ReFacto and Xyntha. The Company's contract manufacturing business, Pfizer CentreOne, consists of its contract manufacturing and active pharmaceutical ingredient sales operation, including manufacturing and supply agreements with Zoetis Inc., and Hospira's One-2-One sterile injectables contract manufacturing operation. Its research focuses on six areas, which include immunology and inflammation, cardiovascular and metabolic diseases, oncology, vaccines, neuroscience and pain, and rare diseases. The Company's subsidiaries include Hospira, Inc. and Medivation, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *